Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMolina Naglazyme Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    ModifiedMolina HealthcarePolicy C28288-A

    Naglazyme (galsulfase) Coverage Criteria

    Customize your policy alerts

    Sign up for Molina Healthcare Policy C28288-A alerts

    Get alerted when Policy C28288-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for intravenous Naglazyme (galsulfase) for members with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). Coverage depends on benefit eligibility, medical necessity, required documentation, specialist involvement, age, dosing, and site-of-care requirements.

    Policy Summary
    PayerMolina Healthcare
    PolicyNaglazyme (galsulfase) Coverage Criteria
    Policy CodePolicy C28288-A
    Change TypeModified
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit prior authorization documentation confirming MPS VI, baseline assessment, qualifying symptoms, specialist involvement, dosing, intravenous administration, and approved site of care.
    SourceLink
    POLICY UPDATE CHANGES

    The Q3 2026 revision updated the references and revised required medical information, continuation-of-therapy requirements, and quantity provisions.

    3 mo–29 yrAge range
    1 mg/kg weeklyDose
    12 monthsAuthorization
    MPS VI

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered indication
    InvestigationalOther uses

    Coverage Criteria

    Initial Therapy

    Covered when all applicable requirements are met:

    Initial therapy

    • Diagnosis and confirmation

      • MPS VI diagnosis: The member has a documented diagnosis of Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome).
      • ONE of

        • Diagnosis is confirmed by reduced fibroblast or leukocyte ARSB enzyme activity.
        • Diagnosis is confirmed by molecular genetic testing of ARSB.
    • Baseline assessment

      • Baseline urinary glycosaminoglycan (GAG) levels are documented.
      • ONE age-appropriate assessment

        • Member 6 years of age or older

          • A baseline 6-minute walk test (6-MWT) is documented.
          • Baseline percent predicted forced vital capacity (FVC) is documented.
        • Member younger than 6 years

          • At least one baseline disease-status measure is documented: upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, or 6-minute walk test.
    • At least ONE qualifying MPS VI symptom

      • At least one qualifying symptom is documented: gait disturbance, growth deficiency, short stature, spinal abnormalities, chest abnormalities, joint abnormalities, respiratory compromise, cardiac valve abnormalities, muscular weakness, visual impairment, hearing loss, or dental abnormalities and oral health challenges.
    • Treatment requirements

      • The member is 3 months through 29 years of age.3 months to 29 years
      • Naglazyme is prescribed by or in consultation with a qualified specialist: a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, a physician specializing in lysosomal storage disorders, or a physician experienced in managing mucopolysaccharidoses (MPS).
      • The dose is 1 mg/kg once weekly.1 mg/kg once weekly
      • Naglazyme is administered intravenously in a non-hospital facility-based location under the Molina Health Care Site of Care program.

    Continuation Therapy

    Covered when all continuation requirements are met:

    Continuation therapy

    • Safety

      • The prescriber attests to, or clinical review finds, no intolerable adverse effects or drug toxicity, including hypersensitivity reactions, anaphylaxis, or severe type III immune-mediated reactions such as membranous glomerulonephritis.
    • Response or stability compared with pretreatment baseline

      • Urinary glycosaminoglycan (GAG) levels have decreased compared with baseline.
      • ONE age-appropriate response or stability measure

        • Member 6 years of age or older

    All other uses of Naglazyme (galsulfase) are considered experimental or investigational and follow Molina's Off-Label policy.

    Coding and Clinical Documentation

    Diagnosis CodeICD-10Covered
    E76.29Other mucopolysaccharidoses
    Coding/Billing InformationHCPCS
    J1458Injection, Galsulfase, 1mg
    Baseline urinary glycosaminoglycan
    Required measureDocumented baseline urinary glycosaminoglycan (GAG) levels
    TimingObtain before initial therapy
    Documentation statusDocumentation is required
    Baseline assessment: Members 6 years or older
    Applicable membersMembers 6 years of age or older
    Required assessment6-minute walk test (6-MWT) and/or percent predicted Forced Vital Capacity (FVC)
    Timing

    Provider Requirements and Submission Guidance

    Prior Authorization

    Obtain initial prior authorization

    Prior authorization is required for Naglazyme (galsulfase) for members 3 months through 29 years of age with documented MPS VI. Initial authorization is available for 12 months when the diagnosis, baseline assessment, symptom, specialist, dosing, intravenous administration, and site-of-care requirements are met.

    • Submit documentation of MPS VI and ARSB confirmation.
    • Use the policy dose of 1 mg/kg once weekly.
    • Document intravenous administration in an approved non-hospital facility-based location.
    Prior Authorization

    Support 12-month continuation authorization

    For reauthorization, submit an attestation or clinical review showing no intolerable adverse effects or drug toxicity and documentation of positive clinical response or disease stability compared with the pretreatment baseline. Continuation authorization is for 12 months.

    • Document decreased urinary GAG levels.

    Disease and Treatment Background

    Mucopolysaccharidosis VI (MPS VI), also known as Maroteaux-Lamy syndrome, is an inherited lysosomal storage disorder caused by deficiency of the ARSB enzyme. This deficiency results in accumulation of dermatan sulfate and chondroitin 4-sulfate glycosaminoglycans, contributing to musculoskeletal, cardiovascular, pulmonary, ophthalmologic, auditory, neurologic, and growth abnormalities. Naglazyme (galsulfase) provides enzyme replacement intended to reduce toxic glycosaminoglycan accumulation.

    Key Definitions

    Mucopolysaccharidosis VI (MPS VI)
    Also known asMaroteaux-Lamy syndrome
    Disease typeInherited lysosomal storage disorder
    Underlying causeMutations affecting the N-acetyl-galactosamine-4-sulfatase (ARSB) enzyme
    Disease characteristicsClinical manifestations may include musculoskeletal, cardiovascular, pulmonary, ophthalmologic, auditory, neurologic, and growth abnormalities
    ARSB confirmation
    Enzyme activity confirmationReduced fibroblast or leukocyte ARSB enzyme activity
    Genetic confirmation

    Naglazyme Initial Authorization Criteria

    Naglazyme Initial Authorization

    Initial authorization requires all of the following:

    Naglazyme initial authorization

    • The member is 3 months through 29 years of age.3 months to 29 years
    • The member has a documented diagnosis of Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome).
    • ONE confirmation method

      • MPS VI is confirmed by reduced fibroblast or leukocyte ARSB enzyme activity.
      • MPS VI is confirmed by molecular genetic testing of ARSB.

    Naglazyme Continuation Criteria

    Naglazyme Continuation

    Continuation authorization requires documentation of all of the following:

    Naglazyme continuation

    • There is no evidence of intolerable adverse effects or drug toxicity, including hypersensitivity reactions, anaphylaxis, or severe type III immune-mediated reactions such as membranous glomerulonephritis.
    • Positive response or disease stability compared with pretreatment baseline

      • Urinary glycosaminoglycan (GAG) levels have decreased compared with baseline.
      • ONE age-appropriate response or stability measure

        • Member 6 years of age or older

    Quantity and Frequency Limits

    Naglazyme quantity limit
    DrugNaglazyme (galsulfase)
    Dose limit1 mg/kg
    FrequencyOnce weekly

    Administration Site Requirements

    Billing Rule

    Use an approved infusion site

    Administer infused Naglazyme under Molina’s Site of Care program in a non-hospital facility-based location. The Site of Care Utilization Management Policy applies.

    • Use a pharmacy or medical benefit place of service that is a non-hospital facility-based location.
    • Review Molina’s Specialty Medication Administration Site of Care Coverage Criteria.
    Policy Summary
    PayerMolina Healthcare
    PolicyNaglazyme (galsulfase) Coverage Criteria
    Policy CodePolicy C28288-A
    Change TypeModified
    Effective DateSep 24, 2026
    Next Review DateJul 1, 2027
    Key ActionSubmit prior authorization documentation confirming MPS VI, baseline assessment, qualifying symptoms, specialist involvement, dosing, intravenous administration, and approved site of care.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical DocumentationProvider Requirements and Submission GuidanceDisease and Treatment BackgroundKey DefinitionsNaglazyme Initial Authorization CriteriaNaglazyme Continuation CriteriaQuantity and Frequency LimitsAdministration Site Requirements
    The 6-minute walk test (6MWT) and/or percent predicted forced vital capacity (FVC) demonstrates clinical response or disease stability.
  1. Member younger than 6 years

    • At least one measure demonstrates response or stability: decreased hepatosplenomegaly, improvement in upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, or 6-minute walk test.
  2. Continuation treatment requirements

    • Naglazyme continues to be prescribed by or in consultation with a qualified specialist; consultation notes are submitted when applicable.
    • Naglazyme is administered intravenously in a non-hospital facility-based location under the Molina Health Care Site of Care program.
  3. Document as a baseline value before initial therapy
    Baseline assessment: Members younger than 6 years
    Applicable membersMembers younger than 6 years
    Required assessmentOne or more age-appropriate disease-status measures
    Available measuresUpper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test
    Continuation urinary glycosaminoglycan
    Required measureDecreased urinary glycosaminoglycan (GAG) levels
    ComparisonCompared with the pretreatment baseline
    Therapy stageRequired for continuation therapy
    Continuation assessment: Members 6 years or older
    Applicable membersMembers 6 years of age and older
    Required assessment6-minute walk test (6MWT) and/or percent predicted forced vital capacity (FVC)
    Expected findingThe assessment must demonstrate positive clinical response or disease stability compared with baseline
    Continuation assessment: Members younger than 6 years
    Applicable membersMembers younger than 6 years of age
    Required assessmentOne or more age-appropriate response or stability measures
    Available measuresDecreased hepatosplenomegaly, improvement in upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, and/or 6-minute walk test
  4. Submit an age-appropriate response or stability measure.
  5. Include specialist consultation notes when the drug is prescribed in consultation.
  6. Documentation Required

    Keep complete supporting records

    Molina may require patient records, test results, and credentials of the provider ordering or performing the drug or service. Additional documentation may be requested for coverage determination, quality improvement, or fraud, waste, and abuse prevention.

    • Provide records and test results supporting medical necessity.
    • Provide ordering or performing provider credentials when requested.
    Documentation Required

    Confirm MPS VI diagnosis

    Submit documentation of Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome). The diagnosis must be confirmed by reduced fibroblast or leukocyte ARSB enzyme activity or by molecular genetic testing of ARSB.

    • Document the MPS VI diagnosis.
    • Submit ARSB enzyme activity or molecular genetic confirmation.
    Documentation Required

    Establish baseline disease status

    For initial therapy, document baseline urinary glycosaminoglycan (GAG) levels and an age-appropriate functional or disease-status assessment. Also document at least one qualifying MPS VI symptom.

    • For members 6 years or older: provide a 6-minute walk test and/or percent predicted FVC.
    • For members younger than 6 years: provide one or more specified measures, including upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, and/or 6-minute walk test.
    • Document at least one qualifying symptom, such as gait, growth, skeletal, respiratory, cardiac, muscular, visual, hearing, dental, or oral-health abnormality.
    Documentation Required

    Document response before reauthorization

    For continuation therapy, document no intolerable adverse effects or drug toxicity and a positive clinical response or disease stability compared with the pretreatment baseline. Supporting evidence includes decreased urinary GAG levels and an age-appropriate response or stability measure.

    • Document absence of intolerable toxicity, including hypersensitivity reactions, anaphylaxis, or severe type III immune-mediated reactions.
    • Submit decreased urinary GAG levels.
    • Submit the applicable functional or disease-status response or stability measure.
    Documentation Required

    Document qualified specialist involvement

    The prescriber must be or consult with a qualified specialist. If prescribed in consultation, submit consultation notes with the initial request and each reauthorization request.

    • Qualified specialists include a board-certified geneticist, metabolic specialist, pediatric neurologist, pediatric developmentalist, endocrinologist, or a physician specializing in lysosomal storage disorders or experienced in managing MPS.
    Documentation Required

    Submit member-specific dosing data

    When dosing is based on weight, body surface area, or another member-specific measurement, submit the applicable measurement as part of the medical necessity review.

    • Include the measurement supporting the requested dose.
    Denial Risk

    Avoid denial for incomplete support

    Coverage or reimbursement may be denied when submitted documentation does not support medical necessity, that the drug is not investigational or experimental, eligibility within the member’s benefits, or appropriate billing practices.

    • Ensure the records support medical necessity and benefit eligibility.
    • Provide documentation showing the use is not investigational or experimental.
    • Avoid documentation patterns indicating inappropriate or excessive billing.
    Denial Risk

    Do not request unsupported uses

    Requests for uses of Naglazyme (galsulfase) other than the policy-supported MPS VI indication are considered experimental or investigational and follow Molina’s Off-Label policy.

    • Use Naglazyme for the policy-supported MPS VI indication.
    Billing Rule

    Bill accurately and verify coverage

    Claims may be rejected or payment may be recovered if the service is not billed appropriately or is not a covered benefit. Listing a code in the policy does not guarantee coverage.

    • Use industry-standard coding practices for all submissions.
    • Confirm that the service is a covered benefit before billing.
    • Code J1458 is described as Injection, Galsulfase, 1mg.
    Molecular genetic testing of ARSB
    Documentation requirementSubmit confirmation of MPS VI by one of these methods
    Mucopolysaccharidosis VI (MPS VI)
    Disease typeInherited lysosomal storage disorder
    Underlying deficiencyARSB enzyme deficiency
    Accumulated substratesDermatan sulfate and chondroitin 4-sulfate glycosaminoglycans
    Galsulfase
    ProductGalsulfase
    EnzymePurified recombinant human N-acetylgalactosamine-4-sulfatase (ARSB)
    Therapeutic useUsed as enzyme replacement therapy in adults and pediatric patients 3 months and older with MPS VI
    Enzyme replacement therapy (ERT)
    Treatment typeEnzyme replacement therapy (ERT)
    What it suppliesAn exogenous enzyme to address the deficient or defective enzyme underlying a lysosomal storage disorder
    Application in MPS VIGalsulfase provides exogenous N-acetylgalactosamine-4-sulfatase (ARSB)
  7. Baseline disease assessment

    • Baseline urinary glycosaminoglycan (GAG) levels are documented.
    • ONE age-appropriate assessment

      • Member 6 years of age or older

        • A baseline 6-minute walk test (6-MWT) and/or percent predicted forced vital capacity (FVC) is documented.
      • Member younger than 6 years

        • At least one baseline measure is documented: upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, hepatosplenomegaly, or 6-minute walk test.
  8. At least one qualifying MPS VI symptom is documented: gait disturbance, growth deficiency, short stature, spinal, chest, joint, respiratory, cardiac valve, muscular, visual, hearing, dental, or oral-health abnormality.
  9. The prescriber is a qualified specialist or has consulted with one; consultation notes are submitted with the request when applicable.
  10. The prescribed dose is 1 mg/kg once weekly.1 mg/kg once weekly
  11. Naglazyme is administered intravenously in a non-hospital facility-based location under the Molina Health Care Site of Care program.
  12. The 6-minute walk test (6MWT) and/or percent predicted forced vital capacity (FVC) demonstrates response or stability.
  13. Member younger than 6 years

    • At least one measure demonstrates response or stability: decreased hepatosplenomegaly, improved upper airway obstruction during sleep, cardiac status, growth velocity, mental development, FVC, or 6-minute walk test.
  14. When Naglazyme is prescribed in consultation with a specialist, consultation notes are submitted with the reauthorization request.